FORM 4

Check this box if no longer subject to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
-------------	------	-------	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average	burden								
hours per response	0.5								

\cup	Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	Filed pursuant to Section 16(a) of the Securitie or Section 30(h) of the Investment Com
		· · ·

94080 (Zip)	n-Derivative S	Securities Acq	uired, Dis _l	oosed of, o	r Bene	ficially	Person	re man One Rep	oorting		
								re than One Rep	orting		
94080								re man One Rep	orting		
0.4000						X	Form filed by On-				
± .	4. If Ar	4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Individual or Joint/Group Filing (Check Applicable				
			ction (Month/I	Day/Year)		below)	below	-			
Name and Address of Reporting Person* McLoughlin Margaret				symbol			10% (
	orting Person*	ret (Middle) C. (Middle) (Middle) 3. Date 10/08	Filed pursuant to Section 16(a) or Section 30(h) of the Invorting Person* 2. Issuer Name and Ticke Cortexyme, Inc. [(Middle) 3. Date of Earliest Transa: 10/08/2021	or Section 30(h) of the investment Contring Person* 2. Issuer Name and Ticker or Trading S Cortexyme, Inc. [CRTX] (Middle) 3. Date of Earliest Transaction (Month/L 10/08/2021	Filed pursuant to Section 16(a) of the Securities Exchange A or Section 30(h) of the Investment Company Act of 19 2. Issuer Name and Ticker or Trading Symbol Cortexyme, Inc. [CRTX] 3. Date of Earliest Transaction (Month/Day/Year) 10/08/2021	Filed pursuant to Section 16(a) of the Securities Exchange Act of 193- or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol Cortexyme, Inc. [CRTX] 3. Date of Earliest Transaction (Month/Day/Year) 10/08/2021	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol Cortexyme, Inc. [CRTX] 3. Date of Earliest Transaction (Month/Day/Year) 10/08/2021 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. India Line)	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol Cortexyme, Inc. [CRTX] 3. Date of Earliest Transaction (Month/Day/Year) 10/08/2021 5. Relationship of Reporting (Check all applicable) X Director Officer (give title below) 6. Individual or Joint/Grou Line)	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol Cortexyme, Inc. [CRTX] 3. Date of Earliest Transaction (Month/Day/Year) 10/08/2021 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Alline)		

M

S⁽¹⁾

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deri Sec Acq (A) (Disp of (I	oosed D) tr. 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)		Amount of		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$17	10/08/2021		M			1,000	(2)	05/07/2029	Common Stock	1,000	\$0.00	84,911	D	

Explanation of Responses:

Common Stock

Common Stock

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2021.

10/08/2021

10/08/2021

2. The option vested as to 1/3rd of the shares on May 8, 2020, with the remaining 2/3rd of shares vesting in equal monthly installments beginning on June 8, 2020 and ending on May 8, 2022.

Remarks:

/s/ Caryn Gordon McDowell, Attorney-in-Fact for Margaret 10/12/2021 **McLoughlin**

** Signature of Reporting Person

(A) or (D)

A

D

Price

\$17

\$88.93

(Instr. 3 and 4)

1,000

0

D

D

Amount

1,000

1,000

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.